Neurobiological Technologies, Inc. (NTII) Stock Price & Analysis

Neurobiological Technologies, Inc. (NTII) Healthcare & Pipeline Overview

Neurobiological Technologies, Inc. is a former biotechnology firm, established in 1987, currently undergoing a formal liquidation and dissolution process initiated in 2009. Its operations are focused on winding down its corporate affairs and distributing remaining assets, rather than active drug development or commercial activities in the healthcare sector.

What Is the Investment Thesis for NTII?

Neurobiological Technologies, Inc. (NTII) presents a unique investment profile, primarily defined by its ongoing plan of liquidation and dissolution, approved in October 2009. The core 'value driver' for current or potential investors is the potential for final distributions of remaining assets to shareholders, rather than operational performance or future growth. The company's market capitalization is reported as $0.00B, reflecting its non-operational status. Key considerations revolve around the efficiency and timeline of the liquidation process, including the resolution of any outstanding liabilities and the monetization of residual assets. With a reported profit margin of 11.9% and a gross margin of 99.5%, these metrics likely reflect past financial activities or specific asset sales rather than ongoing business profitability. The negative beta of -410.84 suggests an inverse and highly volatile relationship with the broader market, which is atypical and may be a statistical anomaly given its non-operational status. Risks include the potential for unforeseen liabilities, the costs associated with the liquidation process, and the uncertainty regarding the final net asset value available for distribution. There are no traditional growth catalysts or operational milestones to monitor, as the company's objective is to cease operations.

Based on FMP financials and quantitative analysis

NTII Key Highlights

Market Capitalization of $0.00B reflects the company's non-operational status and ongoing liquidation process.

• Profit Margin stands at 11.9%, likely indicative of specific asset sales or financial events rather than recurring operational profitability.
• Gross Margin of 99.5% suggests minimal cost of goods sold, consistent with a company no longer engaged in active product development or manufacturing.
• Beta of -410.84 indicates an unusual and highly inverse correlation with market movements, which may be a statistical artifact given the company's liquidation status.
• The company has 4 employees, reflecting a minimal operational footprint focused solely on managing the dissolution process.

Who Are NTII's Competitors?

NTII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTII's Key Strengths?

Clear mandate for liquidation, providing a defined endpoint for corporate activities.

• Minimal operational overhead with only 4 employees, reducing ongoing costs during dissolution.
• Established legal framework for asset distribution to shareholders.

What Are NTII's Weaknesses?

No ongoing revenue-generating operations or active business model.

• Limited transparency and disclosure status (Unknown) for OTC trading.
• Potential for prolonged liquidation process, delaying final distributions.
• Historical drug development pipeline is no longer active or a source of value.

What Are the Key Risks for NTII?

Financial-distress signal — its Altman Z-Score of -2.09 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Prolonged liquidation process, potentially delaying the final distribution of assets to shareholders for an extended period.
• Unforeseen liabilities or legal challenges emerging during the dissolution, which could reduce the net asset value available for distribution.
• Erosion of remaining asset value due to administrative costs, legal fees, and other expenses incurred during the liquidation.
• Difficulty in monetizing remaining assets at favorable prices, especially illiquid or specialized intellectual property.
• Lack of transparency due to 'Unknown' disclosure status, making it challenging for investors to monitor the liquidation progress and financial health.

What Threats Does NTII Face?

• Unforeseen or contingent liabilities emerging during the liquidation process.
• Costs associated with legal and administrative aspects of dissolution eroding asset value.
• Market conditions impacting the value realized from asset divestments.
• Difficulty in attracting liquidity for shares on the OTC market due to liquidation status.

What Are NTII's Competitive Advantages?

• Historically, competitive advantages might have included intellectual property from drug candidates or specialized research expertise in neurobiology.
• Currently, as a company in liquidation, traditional competitive moats are no longer relevant.
• The focus is on administrative efficiency in dissolution, rather than market differentiation or competitive positioning.

What Does NTII Do?

Neurobiological Technologies, Inc. (NTII) was founded in 1987 with a strategic focus on the development of investigational drugs aimed at treating various human diseases within the biotechnology sector. For many years, the company engaged in preclinical and clinical research, striving to bring innovative therapeutic solutions to market. However, a significant shift in its corporate trajectory occurred in October 2009 when its stockholders approved a comprehensive plan of liquidation and dissolution. This pivotal decision marked the cessation of its active drug development programs and a transition to an orderly winding down of all corporate operations. Based in Emeryville, California, the company, which once aimed to contribute to advancements in neurobiological treatments, now functions primarily as an entity managing its dissolution process. With a notably small operational footprint, evidenced by its four employees, NTII's current activities are centered on resolving outstanding liabilities, managing any remaining assets, and ultimately distributing the net proceeds to its shareholders in accordance with the approved liquidation plan. Its historical market position as an early-stage drug developer has been superseded by its current status as a company in the final stages of corporate existence, with no ongoing research, development, or commercial product offerings.

What Products and Services Does NTII Offer?

• Manages the formal liquidation and dissolution process approved by stockholders in October 2009.
• Previously focused on developing investigational drugs for the treatment of human diseases.
• Engaged in research and development activities within the biotechnology sector prior to its liquidation plan.
• Operates with a minimal team of 4 employees, primarily for administrative oversight of the dissolution.
• Based in Emeryville, California, serving as its corporate headquarters for liquidation activities.
• Does not currently engage in active drug development, manufacturing, or commercial sales.
• Aims to resolve outstanding liabilities and distribute remaining assets to shareholders.

How Does NTII Make Money?

• Historically, the business model involved research and development of investigational drugs, with potential revenue from successful commercialization or licensing agreements.
• Currently, the business model is centered on the orderly winding down of corporate operations.
• Financial activities primarily involve the management and divestment of remaining assets.
• Focus is on fulfilling legal and fiduciary duties related to the liquidation plan.
• Any financial returns are derived from the distribution of net assets to shareholders, not from ongoing operational profits.

What Industry Does NTII Operate In?

Neurobiological Technologies, Inc. (NTII) historically operated within the highly specialized and research-intensive biotechnology industry, a sub-sector of healthcare focused on developing drug therapies and diagnostic tools. This industry is characterized by significant R&D investments, lengthy regulatory approval processes, and high-risk, high-reward ventures. Companies typically compete on the efficacy and safety of their investigational drugs, intellectual property, and ability to navigate clinical trials. However, NTII's current status as a company under a plan of liquidation and dissolution, approved in October 2009, means it no longer actively participates in this competitive landscape. Its former positioning involved contributing to the pipeline of investigational drugs for human diseases. Today, it exists outside the active market trends and competitive dynamics of the biotechnology sector, with its focus entirely on administrative closure rather than innovation or market share.

Who Are NTII's Key Customers?

• Historically, potential customers would have been healthcare providers and patients benefiting from its investigational drugs.
• Currently, the company does not have active customers for products or services.
• The primary stakeholders are its shareholders, awaiting the final distributions from the liquidation process.

Company Profile

Neurobiological Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO John B. Stuppin. NTII has traded publicly since 1994.

Neurobiological Technologies, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 104.7% below estimates on average.

Neurobiological Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.09 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Neurobiological Technologies, Inc. stands at 24.9%, a gauge of how efficiently it converts shareholder capital into profit. NTII trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.10x. A current ratio of 35.34 indicates the company holds enough short-term assets to cover its near-term obligations.

Insider Activity

12 transactions · 0 purchases, 0 sales, 12 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

NTII Financials

NTII Latest News

No recent news available for NTII.

NTII Analyst Consensus

NTII MoonshotScore

Common Questions About NTII (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources